TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07085767: Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Sponsor: Olema Pharmaceuticals, Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 1000 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$5,051,508

Rescue Site Savings

+$3,345,804

Unlock Full NCT07085767 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07085767 Rescue Dossier →